// App-Quantinova.ai

627 : Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

Researchers

Presenter

  • Cristina Cruz Zambrano

Principal Investigators

  • Jean-Pascal H. Machiels

  • Catherine Herremans

  • Markus Joerger

  • Jesus Corral Jaime

  • Maria Alsina

  • Fabienne Baffert

  • David Demanse

  • Vincent Duval

  • Alex Morozov

  • Ahmad Awada

  • Roger von Moos

  • Neeltje Steeghs

  • Jordi Rodon Ahnert

  • Peggy De Mesmaeker

  • Heike Richly

  • Luc Dirix

  • Dagmar Hess

  • Luis Paz-Ares

Medical Centers

  • Sint-Augustinus Hospital, Antwerpen, Belgium

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium

  • Cantonal Hospital, St. Gallen, SwitzerlandNovartis Pharma AG, Basel, SwitzerlandUniversity Hospital Virgen del Rocio, Seville, Spain

  • Kantonsspital Graubuenden, Graubuenden, Switzerland

  • West German Cancer Center, University Hospital, Essen, Germany

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

Locations

  • Netherlands

  • Spain

  • Germany

  • Switzerland

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • buparlisib

  • Paclitaxel

  • BKM-120

Outcome

  • Negative

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01285466

Sponsors

  • Novartis

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved